Cargando…

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK

Background: Skin toxicity is a common adverse event during cetuximab (Cmab) treatment. However, few reports have investigated the correlation between skin toxicity and the efficacy of Cmab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Methods: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uozumi, Shinya, Enokida, Tomohiro, Suzuki, Shinya, Nishizawa, Aya, Kamata, Hayato, Okano, Tomoka, Fujisawa, Takao, Ueda, Yuri, Okano, Susumu, Tahara, Makoto, Yamaguchi, Masakazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300475/ https://www.ncbi.nlm.nih.gov/pubmed/30619755 http://dx.doi.org/10.3389/fonc.2018.00616

Ejemplares similares

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
por: Ueda, Yuri, et al.
Publicado: (2020)

Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab
por: Enokida, Tomohiro, et al.
Publicado: (2016)

A pharmacist-led opioid de-escalation program after completion of chemoradiotherapy in locally advanced head and neck cancer
por: Horinouchi, Ai, et al.
Publicado: (2023)

Retrospective analysis of premedication, glucocorticosteroids, and H(1)-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer
por: Ikegawa, Kiwako, et al.
Publicado: (2017)

Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study
por: Matsuyama, Chihiro, et al.
Publicado: (2023)

A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma
por: Tahara, Makoto, et al.
Publicado: (2021)

A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
por: Enokida, Tomohiro, et al.
Publicado: (2020)

Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study
por: Takeshita, Naohiro, et al.
Publicado: (2022)

Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer
por: Shibutani, Yuma, et al.
Publicado: (2023)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
por: Zenda, Sadamoto, et al.
Publicado: (2019)

Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib
por: Suzuki, Shinya, et al.
Publicado: (2020)

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
por: Onaga, Ryutaro, et al.
Publicado: (2023)

Phase II Study of Cetuximab Plus Concomitant Boost Radiotherapy in Japanese Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
por: Okano, Susumu, et al.
Publicado: (2013)

Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions
por: Enokida, Tomohiro, et al.
Publicado: (2021)

Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma
por: Ogawa-Morita, Tomoko, et al.
Publicado: (2017)

A Case Series on Pain Accompanying Photoimmunotherapy for Head and Neck Cancer
por: Shibutani, Yuma, et al.
Publicado: (2023)

Salvage Reconstructive Surgery During Nivolumab Therapy for a Patient With Hypopharyngeal Cancer
por: Tsushima, Nayuta, et al.
Publicado: (2020)

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions
por: Guigay, Joël, et al.
Publicado: (2019)

Management of VEGFR-Targeted TKI for Thyroid Cancer
por: Enokida, Tomohiro, et al.
Publicado: (2021)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

Evaluation of the impact of a flowchart-type leaflet for cancer inpatients
por: Suzuki, Shinya, et al.
Publicado: (2014)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck
por: Perri, Francesco, et al.
Publicado: (2009)

Efficacy of gemcitabine and cetuximab combination treatment in head and neck squamous cell carcinoma
por: MASEKI, SHINICHIRO, et al.
Publicado: (2013)

iPS cell technologies: significance and applications to CNS regeneration and disease
por: Okano, Hideyuki, et al.
Publicado: (2014)

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
por: Hoellein, Alexander, et al.
Publicado: (2011)

Retinal detachment and retinoschisis associated with optic disc pit in peripapillary staphyloma
por: Okano, Kana, et al.
Publicado: (2022)

Platinum-based Chemotherapy Plus Cetuximab for the First-line Treatment of Japanese Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of a Phase II Trial
por: Yoshino, Takayuki, et al.
Publicado: (2013)

Landscape of natural killer cell activity in head and neck squamous cell carcinoma
por: Charap, Andrew J, et al.
Publicado: (2020)

Effects of Cetuximab and Erlotinib on the behaviour of cancer stem cells in head and neck squamous cell carcinoma
por: Setúbal Destro Rodrigues, Maria Fernanda, et al.
Publicado: (2018)

Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck
por: Trieu, Vanessa, et al.
Publicado: (2018)

Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Taberna, Miren, et al.
Publicado: (2019)

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status
por: Baysal, Hasan, et al.
Publicado: (2020)

Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation
por: Enokida, Tomohiro, et al.
Publicado: (2017)

Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Charalambakis, Nikolaos, et al.
Publicado: (2013)

Paired Synchronous Rhythmic Finger Tapping without an External Timing Cue Shows Greater Speed Increases Relative to Those for Solo Tapping
por: Okano, Masahiro, et al.
Publicado: (2017)

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab
por: Kono, Scott A., et al.
Publicado: (2012)

Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
por: BAUMAN, JESSICA, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0he9ugh1pgoura9tnermf1o3mr